Radioimmunotherapy of Neoplastic Meningitis in Rats Using an α-Particle-emitting Immunoconjugate

Because of their short range and high linear energy transfer, α-particles may be particularly effective in the treatment of neoplastic meningitis. Monoclonal antibody 81C6 was labeled with α-particle-emitting 211At using N -succinimidyl3-[211At]astatobenzoate, and the efficacy and toxicity of this immunoconjugate were evaluated in an athymic rat model. Animals were given injections via a chronic indwelling catheter with 5 × 105 TE-671 human rhabdomyosarcoma cells and treated 8 days later with single intrathecal doses of either saline or 4–18 µCi of 211At-labeled specific 81C6 antibody or isotype-matched control 211At-labeled 45.6 antibody. In the first experiment, 4, 7, and 13 µCi 211At-labeled 81C6 produced statistically significant ( P = 0.004-0.02) increases in median survival of 33, 29, and 51%, respectively, as compared with saline. Two of 10 animals receiving the 13-µCi dose lived for 6 months before being killed for histological analysis. In the second experiment, 12 µCi of 211At-labeled 45.6 did not increase median survival significantly relative to saline control, while 12 µCi of 211At-labeled 81C6 increased median survival by 113% ( P < 0.005) and resulted in 33% apparent cures. Five of 10 animals receiving 18 µCi of 211At-labeled 81C6 survived until they were killed at 295 days. An additional study was performed in animals given intrathecal injections of 5 × 106 TE-671 cells and given a single dose of 18 µCi of 211At-labeled 81C6 or 211At-labeled 45.6. At this higher cell number, significantly prolonged survival was still seen for specific antibody as compared with saline ( P < 0.001) and control antibody ( P < 0.05). These results suggest that treatment with 211At-labeled monoclonal antibodies may be a valuable approach for neoplastic meningitis.

[1]  R. Jaszczak,et al.  Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. , 1993, Investigative radiology.

[2]  D. Bigner,et al.  Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates , 1992, International journal of cancer.

[3]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[4]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. , 1991, Microvascular research.

[5]  C. Pelizzari,et al.  Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. , 1990, International journal of radiation oncology, biology, physics.

[6]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[7]  A. Barrett,et al.  Dosimetric model for antibody targeted radionuclide therapy of tumor cells in cerebrospinal fluid. , 1990, Cancer research.

[8]  D. Bigner,et al.  Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. , 1989, Cancer research.

[9]  D. Bigner,et al.  Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Coleman,et al.  Alpha particle radio-immunotherapy: animal models and clinical prospects. , 1989, International journal of radiation oncology, biology, physics.

[11]  R. Coleman,et al.  Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. , 1989, Cancer research.

[12]  J. Humm A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. , 1987, International journal of radiation oncology, biology, physics.

[13]  Hugh Davson,et al.  Physiology and Pathophysiology of the Cerebrospinal Fluid , 1987 .

[14]  S. Mirzadeh,et al.  211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. , 1984, International journal of radiation oncology, biology, physics.

[15]  D. Bigner,et al.  Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. , 1983, Cancer research.

[16]  M. Schork,et al.  Statistics With Applications to the Biological and Health Sciences. , 1971 .

[17]  J. G. Hamilton,et al.  The accumulation and destructive action of astatine 211 (eka-iodine) in the thyroid gland of rats and monkeys. , 1954, The Journal of clinical endocrinology and metabolism.

[18]  K. Fujimori,et al.  Barrier ' ' Microscopic Tumor Nodules : Consequences of a ' ' Binding Site An Analysis of Monoclonal Antibody Distribution in Updated , 2006 .

[19]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. , 1991 .

[20]  I. Brown Astatine-211: its possible applications in cancer therapy. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[21]  S. Pizzo,et al.  Immunochemical and biochemical characterization of a glioma‐associated extracellular matrix glycoprotein , 1985, Journal of cellular biochemistry.

[22]  E. Hall,et al.  Radiobiology for the radiologist , 1973 .